Free Trial
CVE:LXG

LexaGene (LXG) Stock Price, News & Analysis

LexaGene logo
C$0.10 -0.03 (-19.23%)
As of 02/21/2023

About LexaGene Stock (CVE:LXG)

Key Stats

Today's Range
C$0.10
C$0.14
50-Day Range
C$0.11
C$0.11
52-Week Range
C$0.07
C$0.31
Volume
2.14 million shs
Average Volume
170,061 shs
Market Capitalization
C$14.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive LXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LexaGene and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LXG Stock News Headlines

Pamapol Ord Share Price (0LXG)
Biosynex SA ALBIO
Nobody Understands Why Trump Is Invading Iran (here’s the answer)
Most investors are reacting to the Iran strikes without understanding the underlying motive driving the decision. Addison Wiggin, Founder of Grey Swan Investment Fraternity, says there is a hidden reason behind the bombing - and knowing it could change how you position your money right now.tc pixel
Cyclopharm Ltd CYC
Lexagene Holdings Inc (LXGh)
Zhejiang Gongdong Medical Technology Co Ltd Class A
IIROC Trading Halt - LXG
See More Headlines

LXG Stock Analysis - Frequently Asked Questions

LexaGene's stock was trading at C$0.11 at the beginning of the year. Since then, LXG shares have increased by 0.0% and is now trading at C$0.11.

Shares of LXG stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that LexaGene investors own include Citius Pharmaceuticals (CTXR), Avino Silver & Gold Mines (ASM), Athersys (ATHX), Bionano Genomics (BNGO), EQT (EQT), Inovio Pharmaceuticals (INO) and NIO (NIO).

Industry, Sector and Symbol

Stock Exchange
CVE
Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
N/A
Current Symbol
CVE:LXG
CIK
N/A
Fax
N/A
Employees
41
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
C($0.08)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-C$8.54 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-339.54%
Return on Assets
-120.21%

Debt

Debt-to-Equity Ratio
138.01
Current Ratio
1.39
Quick Ratio
1.13

Sales & Book Value

Annual Sales
C$110.93 thousand
Price / Sales
133.13
Cash Flow
C$0.00 per share
Price / Cash Flow
21.25
Book Value
C$0.01 per share
Price / Book
10.50

Miscellaneous

Outstanding Shares
140,640,000
Free Float
N/A
Market Cap
C$14.77 million
Optionable
Not Optionable
Beta
2.26
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.

Get This Free Report

This page (CVE:LXG) was last updated on 5/9/2026 by MarketBeat.com Staff.
From Our Partners